Equity Overview
Price & Market Data
Price: $0.819
Daily Change: +$0.001 / 0.12%
Daily Range: $0.71 - $0.84
Market Cap: $5,299,930
Daily Volume: 255,775
Performance Metrics
1 Week: 27.86%
1 Month: -8.92%
3 Months: -36.32%
6 Months: -51.73%
1 Year: -73.32%
YTD: -11.16%
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.